Comparative Pharmacology
Head-to-head clinical analysis: POTASSIUM CHLORIDE 0 037 IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5 AND LACTATED RINGER S IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: POTASSIUM CHLORIDE 0 037 IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5 AND LACTATED RINGER S IN PLASTIC CONTAINER.
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER vs POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Potassium chloride dissociates to provide potassium ions, which are essential for maintaining intracellular osmolarity, acid-base balance, and normal nerve conduction and muscle contraction, including cardiac muscle. Dextrose provides a source of calories and may prevent ketosis.
Potassium chloride provides potassium ions for maintenance of electrolyte balance and repolarization of cell membranes. Dextrose 5% provides caloric supplementation and may enhance potassium uptake into cells via insulin-mediated mechanisms. Lactated Ringer's solution provides isotonic crystalloid fluid, electrolytes (sodium, calcium, lactate), and buffer (bicarbonate precursor) to maintain intravascular volume and acid-base balance.
Intravenous infusion of potassium chloride 0.037% in dextrose 5% at a rate not exceeding 10 mEq/hour of potassium and a maximum concentration of 40 mEq/L in peripheral veins; dose determined by serum potassium level and clinical need, typically 20-40 mEq per day for mild depletion.
Intravenous infusion: 10–20 mEq/hour, not to exceed 20–40 mEq in 4 hours or 150 mEq per 24 hours. Rate: max 10 mEq/hour (1 mEq/mL concentration).
None Documented
None Documented
Potassium has a complex disposition; the distribution between intracellular and extracellular compartments affects half-life. In normal renal function, the serum potassium half-life is approximately 4-6 hours after a dose, but this is not a true terminal half-life due to extensive tissue buffering. The body's total potassium turnover half-life is around 25-30 hours. In patients with renal impairment, half-life is prolonged proportionally to creatinine clearance.
Potassium does not have a classical elimination half-life as it is an electrolyte with complex distribution and regulation. After a single IV dose, plasma levels decline rapidly due to redistribution, with an initial distribution half-life of about 1 hour. The terminal phase reflects slow equilibration with total body stores and is influenced by renal function; in anephric patients, the effective half-life is extended significantly.
Potassium is primarily excreted renally (>90%) with about 10% excreted in feces via gastrointestinal secretion. Minimal excretion occurs through sweat. Renal handling involves glomerular filtration, proximal tubular reabsorption, and potassium secretion in the distal tubule and collecting duct regulated by aldosterone. Excretion is not linear and depends on potassium balance, renal function, and hormonal influences.
Potassium is primarily excreted renally (90%) via glomerular filtration and active secretion in the distal tubule; approximately 10% is lost in feces. In patients with normal renal function, urinary excretion is increased when intake is high. In the presence of renal impairment, elimination is decreased, leading to hyperkalemia risk. Dialysis (hemodialysis or peritoneal dialysis) can remove potassium.
Category C
Category C
Electrolyte Supplement
Electrolyte Supplement